Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Novo Nordisk Archives
Print | Email | Share | Comments (0)

The Need for Speed-New Fast-Acting Insulin Available for People With Diabetes


Nov 1, 2001
On September 18, Novo Nordisk Pharma-ceuticals announced that its rapid-acting insulin aspart (NovoLog) is now available in the United States.

According to Novo Nordisk, NovoLog has faster absorption, a faster onset and shorter duration of action than Regular human insulin.

"Regular human insulin acts more slowly so patients must usually administer it 30 minutes before eating," says Novo in a September 18 press release.

NovoLog safety and tolerability was com-parable to regular human insulin in three large-scale clinical trials.

Novo says NovoLog is "indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia."

In addition, because it has a more rapid onset and shorter duration of action than Regular human insulin, Novo advises that NovoLog be used in regimens together with intermediate or long-acting insulin.

"É Injection of NovoLog should immediately be followed by a meal."

John Whisnant, vice president of medical at Novo Nordisk, says, "Hypoglycemia is the most common side effect of NovoLog, as for all insulins, but the frequency of nocturnal hypos may be less."

NovoLog is available in cartridges for use with the NovoPen 3, Innovo and soon to be available in InDuo insulin delivery systems.

Spokespersons at Novo Nordisk say there is no data comparing NovoLog to its rapid-acting insulin counterpart Humalog, as no studies have yet been conducted.

Full prescribing infor-mation for NovoLog is avail-able by contacting the manufacturer at (800) 727-6500. For further company information visit www. novonordisk. com.



-D. Trecroci

Categories: Diabetes, Diabetes, General, Insulin, Low Blood Sugar, Novo Nordisk



You May Also Be Interested In...


Click Here To View Or Post Comments

Nov 1, 2001

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.